|
1
|
Bridgewater JA, Goodman KA, Kalyan A and
Mulcahy MF: Biliary tract cancer: Epidemiology, radiotherapy, and
molecular profiling. Am Soc Clin Oncol Educ Book. 35:e194–e203.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rizvi S and Gores GJ: Pathogenesis,
diagnosis, and management of cholangiocarcinoma. Gastroenterology.
145:1215–1229. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nagino M, Ebata T, Yokoyama Y, Igami T,
Sugawara G, Takahashi Y and Nimura Y: Evolution of surgical
treatment for perihilar cholangiocarcinoma: A single-center 34-year
review of 574 consecutive resections. Ann Surg. 258:129–140. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Malenica I, Donadon M and Lleo A:
Molecular and immunological characterization of biliary tract
cancers: A paradigm shift towards a personalized medicine. Cancers
(Basel). 12:21902020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lou Q, Liu R, Yang X, Li W, Huang L, Wei
L, Tan H, Xiang N, Chan K, Chen J and Liu H: miR-448 targets IDO1
and regulates CD8(+) T cell response in human colon cancer. J
Immunother Cancer. 7:2102019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Harden JL and Egilmez NK: Indoleamine
2,3-dioxygenase and dendritic cell tolerogenicity. Immunol Invest.
41:738–764. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Moon YW, Hajjar J, Hwu P and Naing A:
Targeting the indoleamine 2,3-dioxygenase pathway in cancer. J
Immunother Cancer. 3:512015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Brochez L, Chevolet I and Kruse V: The
rationale of indoleamine 2,3-dioxygenase inhibition for cancer
therapy. Eur J Cancer. 76:167–182. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Munn DH, Zhou M, Attwood JT, Bondarev I,
Conway SJ, Marshall B, Brown C and Mellor AL: Prevention of
allogeneic fetal rejection by tryptophan catabolism. Science.
281:1191–1193. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yu CP, Fu SF, Chen X, Ye J, Ye Y, Kong LD
and Zhu Z: The clinicopathological and prognostic significance of
IDO1 expression in human solid tumors: Evidence from a systematic
review and meta-analysis. Cell Physiol Biochem. 49:134–143. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Frumento G, Rotondo R, Tonetti M, Damonte
G, Benatti U and Ferrara GB: Tryptophan-derived catabolites are
responsible for inhibition of T and natural killer cell
proliferation induced by indoleamine 2,3-dioxygenase. J Exp Med.
196:459–468. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Soliman H, Rawal B, Fulp J, Lee JH, Lopez
A, Bui MM, Khalil F, Antonia S, Yfantis HG, Lee DH, et al: Analysis
of indoleamine 2–3 dioxygenase (IDO1) expression in breast cancer
tissue by immunohistochemistry. Cancer Immunol Immunother.
62:829–837. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Riesenberg R, Weiler C, Spring O, Eder M,
Buchner A, Popp T, Castro M, Kammerer R, Takikawa O, Hatz RA, et
al: Expression of indoleamine 2,3-dioxygenase in tumor endothelial
cells correlates with long-term survival of patients with renal
cell carcinoma. Clin Cancer Res. 13:6993–7002. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Ino K, Yoshida N, Kajiyama H, Shibata K,
Yamamoto E, Kidokoro K, Takahashi N, Terauchi M, Nawa A, Nomura S,
et al: Indoleamine 2,3-dioxygenase is a novel prognostic indicator
for endometrial cancer. Br J Cancer. 95:1555–1561. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gao YF, Peng RQ, Li J, Ding Y, Zhang X, Wu
XJ, Pan ZZ, Wan DS, Zeng YX and Zhang XS: The paradoxical patterns
of expression of indoleamine 2,3-dioxygenase in colon cancer. J
Transl Med. 7:712009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Inaba T, Ino K, Kajiyama H, Shibata K,
Yamamoto E, Kondo S, Umezu T, Nawa A, Takikawa O and Kikkawa F:
Indoleamine 2,3-dioxygenase expression predicts impaired survival
of invasive cervical cancer patients treated with radical
hysterectomy. Gynecol Oncol. 117:423–428. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ye J, Liu H, Hu Y, Li P, Zhang G and Li Y:
Tumoral indoleamine 2,3-dioxygenase expression predicts poor
outcome in laryngeal squamous cell carcinoma. Virchows Arch.
462:73–81. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Jacquemier J, Bertucci F, Finetti P,
Esterni B, Charafe-Jauffret E, Thibult ML, Houvenaeghel G, Van den
Eynde B, Birnbaum D, Olive D and Xerri L: High expression of
indoleamine 2,3-dioxygenase in the tumour is associated with
medullary features and favourable outcome in basal-like breast
carcinoma. Int J Cancer. 130:96–104. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ishio T, Goto S, Tahara K, Tone S, Kawano
K and Kitano S: Immunoactivative role of indoleamine
2,3-dioxygenase in human hepatocellular carcinoma. J Gastroenterol
Hepatol. 19:319–326. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Amin MB, Edge SB, Greene FL, Byrd DR,
Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR,
Sullivan DC, et al: AJCC Cancer Staging Manual. 8th edition.
Springer; New York, USA: pp. 317–325. 2017
|
|
21
|
Ferdinande L, Decaestecker C, Verset L,
Mathieu A, Moles Lopez X, Negulescu AM, Van Maerken T, Salmon I,
Cuvelier CA and Demetter P: Clinicopathological significance of
indoleamine 2,3-dioxygenase 1 expression in colorectal cancer. Br J
Cancer. 106:141–147. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ma W, Duan H, Zhang R, Wang X, Xu H, Zhou
Q and Zhang L: High expression of indoleamine 2, 3-dioxygenase in
adenosquamous lung carcinoma correlates with favorable patient
outcome. J Cancer. 10:267–276. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lugli A, Karamitopoulou E, Panayiotides I,
Karakitsos P, Rallis G, Peros G, Iezzi G, Spagnoli G, Bihl M,
Terracciano L and Zlobec I: CD8+ lymphocytes/tumour-budding index:
An independent prognostic factor representing a ‘pro-/anti-tumour’
approach to tumour host interaction in colorectal cancer. Br J
Cancer. 101:1382–1392. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Oshikiri T, Miyamoto M, Shichinohe T,
Suzuoki M, Hiraoka K, Nakakubo Y, Shinohara T, Itoh T, Kondo S and
Katoh H: Prognostic value of intratumoral CD8+ T lymphocyte in
extrahepatic bile duct carcinoma as essential immune response. J
Surg Oncol. 84:224–228. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fukunaga A, Miyamoto M, Cho Y, Murakami S,
Kawarada Y, Oshikiri T, Kato K, Kurokawa T, Suzuoki M, Nakakubo Y,
et al: CD8+ tumor-infiltrating lymphocytes together with CD4+
tumor-infiltrating lymphocytes and dendritic cells improve the
prognosis of patients with pancreatic adenocarcinoma. Pancreas.
28:e26–e31. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Galon J, Costes A, Sanchez-Cabo F,
Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M,
Berger A, Wind P, et al: Type, density, and location of immune
cells within human colorectal tumors predict clinical outcome.
Science. 313:1960–1964. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mahmoud SM, Paish EC, Powe DG, Macmillan
RD, Grainge MJ, Lee AH, Ellis IO and Green AR: Tumor-infiltrating
CD8+ lymphocytes predict clinical outcome in breast cancer. J Clin
Oncol. 29:1949–1955. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mlecnik B, Tosolini M, Kirilovsky A,
Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman
WH, Pagès F and Galon J: Histopathologic-based prognostic factors
of colorectal cancers are associated with the state of the local
immune reaction. J Clin Oncol. 29:610–618. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kitano Y, Okabe H, Yamashita YI, Nakagawa
S, Saito Y, Umezaki N, Tsukamoto M, Yamao T, Yamamura K, Arima K,
et al: Tumour-infiltrating inflammatory and immune cells in
patients with extrahepatic cholangiocarcinoma. Br J Cancer.
118:171–180. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Goeppert B, Frauenschuh L, Zucknick M,
Stenzinger A, Andrulis M, Klauschen F, Joehrens K, Warth A, Renner
M, Mehrabi A, et al: Prognostic impact of tumour-infiltrating
immune cells on biliary tract cancer. Br J Cancer. 109:2665–2674.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Brandacher G, Perathoner A, Ladurner R,
Schneeberger S, Obrist P, Winkler C, Werner ER, Werner-Felmayer G,
Weiss HG, Göbel G, et al: Prognostic value of indoleamine
2,3-dioxygenase expression in colorectal cancer: Effect on
tumor-infiltrating T cells. Clin Cancer Res. 12:1144–1151. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Munn DH and Mellor AL: IDO in the tumor
microenvironment: Inflammation, counter-regulation, and tolerance.
Trends Immunol. 37:193–207. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dunn GP, Bruce AT, Ikeda H, Old LJ and
Schreiber RD: Cancer immunoediting: From immunosurveillance to
tumor escape. Nat Immunol. 3:991–998. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Maggi E, Giudizi MG, Biagiotti R,
Annunziato F, Manetti R, Piccinni MP, Parronchi P, Sampognaro S,
Giannarini L, Zuccati G and Romagnani S: Th2-like CD8+ T cells
showing B cell helper function and reduced cytolytic activity in
human immunodeficiency virus type 1 infection. J Exp Med.
180:489–495. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ludovini V, Bianconi F, Siggillino A,
Vannucci J, Baglivo S, Berti V, Tofanetti FR, Reda MS, Bellezza G,
Mandarano M, et al: High PD-L1/IDO-2 and PD-L2/IDO-1 Co-expression
levels are associated with worse overall survival in resected
non-small cell lung cancer patients. Genes (Basel). 12:2732021.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang ML, Kem M, Mooradian MJ, Eliane JP,
Huynh TG, Iafrate AJ, Gainor JF and Mino-Kenudson M: Differential
expression of PD-L1 and IDO1 in association with the immune
microenvironment in resected lung adenocarcinomas. Mod Pathol.
32:511–523. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Prendergast GC, Malachowski WP, DuHadaway
JB and Muller AJ: Discovery of IDO1 inhibitors: From bench to
bedside. Cancer Res. 77:6795–6811. 2017. View Article : Google Scholar : PubMed/NCBI
|
